article thumbnail

Epidemiology, Pathophysiology, Diagnosis and Management of Chronic Right?Sided Heart Failure and Tricuspid Regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC

European Journal of Heart Failure

Abstract Right-sided heart failure and tricuspid regurgitation are common and strongly associated with poor quality of life and an increased risk of heart failure hospitalizations and death. This article is protected by copyright. All rights reserved.

article thumbnail

Changes in right ventricular function and clinical outcomes following tricuspid transcatheter edge?to?edge repair

European Journal of Heart Failure

Changes in right ventricular (RV) function and clinical outcomes after tricuspid transcatheter edge-to-edge repair (T-TEER). Among patients with baseline RVFAC <35%, a smaller RV diameter and a greater reduction of tricuspid regurgitation were predictors for the RV responder.

article thumbnail

Tricuspid Regurgitation Progression and Clinical Implications

American College of Cardiology

What are the predictors of tricuspid regurgitation (TR) progression and the prognostic impact of TR progression?

article thumbnail

Effects of ICD Leads on Tricuspid Valve and Right Ventricle

American College of Cardiology

What is the effect of a transvenous implantable cardioverter-defibrillator (TV-ICD) on tricuspid regurgitation (TR) severity, and secondarily, on right ventricular (RV) size and function?

article thumbnail

Tricuspid Valve Treatments Safe, Effective and Improve Quality of Life

American College of Cardiology

Food and Drug Administration (FDA) this year for tricuspid regurgitation (TR) are safe, effective and improve quality of life (QOL) at one year, according to studies published in JACC and simultaneously being presented at TCT 2024. Two devices approved by the U.S.

article thumbnail

Trial to Evaluate Cardiovascular Outcomes in Patients Treated With the Tricuspid Valve Repair System Pivotal

American College of Cardiology

The goal of the TRILUMINATE Pivotal trial was to evaluate percutaneous tricuspid valve transcatheter edge-to-edge repair (TEER) compared with medical therapy among patients with symptomatic severe tricuspid regurgitation.

article thumbnail

ACC CardiaCast’s PulseCheck: Tricuspid Valve Disease

American College of Cardiology

In this episode, the focus is on tricuspid valve disease. In this panel discussion, host Andrea Price MS, AACC brings together Marcus Burns, DNP, Kristen deAlmeida, PharmD, and Bailey Estes MSN, AGNP-C, to explore best practices related to structural heart disease.